Skip to main content

Press releases

2018-09-18
STOCKHOLM, September 18th, 2018, Moberg Pharma AB (OMX: MOB) has signed an exclusive license agreement with Cipher Pharmaceuticals (“Cipher”) for MOB-015 in Canada. Cipher will commercialize MOB-015 in Canada upon completed phase 3 studies and registration. Under the agreement, Moberg Pharma is eligible to receive USD 14.6 million in one-time payments and milestones, as well as royalties on net sales in Canada.
2018-09-11
STOCKHOLM, September 11th, 2018, Moberg Pharma AB (OMX: MOB) has completed the recruitment of 365 patients with onychomycosis (nail fungus) for the ongoing MOB-015 phase 3 study in North America. The aim is to provide a pivotal part of the clinical data set for registration and commercialization of MOB-015. Topline results are expected in the fourth quarter of 2019.
2018-08-13
STOCKHOLM, August 13th, 2018, Moberg Pharma AB (OMX: MOB) announces the appointment of Shaw Sorooshian as Vice President and Chief Medical Officer of Moberg Pharma. Shaw Sorooshian will during the fall be joining the management team at Moberg Pharma coming from a previous position as Senior Director Global Medical Affairs at Sobi AB.
2018-08-07
STRONG GROWTH, HIGHER PROFITABILITY AND PIPELINE PROGRESS
2018-07-30
STOCKHOLM, July 30th, 2018 – On August 7th 2018, at 08:00 am (CET), Moberg Pharma AB (OMX: MOB) will present its interim report for January - June 2018. Investors, analysts and journalists are hereby invited to participate in a teleconference at 3:00 pm (CET) on the same date.
2018-06-29
STOCKHOLM, June 29th, 2018, Moberg Pharma AB (OMX: MOB) announced that the total number of common shares in the company has increased to 17,703,762. The 263,000 newly issued shares are held by the company to secure its commitments under incentive programmes.
2018-06-20
STOCKHOLM, June 20th, 2018, Moberg Pharma AB (OMX: MOB) announced the appointment of Mark Beveridge as Vice President Finance and member of the management team, effective from July 1st 2018. Mark Beveridge has held various finance positions at Moberg Pharma since 2015 and was previously a senior advisor to the company. 
2018-05-25
STOCKHOLM, May 25th, 2018, Moberg Pharma AB (OMX: MOB) announced that the board of directors exercises authorizations to issue and repurchase C-shares, and converts C-shares to common shares, to secure the company’s commitments under incentive programme.
2018-05-15
STOCKHOLM, MAY 15th, 2018. Moberg Pharma AB’s (“Company”) Annual General Meeting took place on Tuesday, May 15th, 2018 in the Company´s premises in Bromma.
2018-05-08
SIGNIFICANT GROWTH FOR ALL KEY BRANDS
2018-05-02
STOCKHOLM, May 2nd, 2018, Moberg Pharma AB (OMX: MOB) announced that the United States Patent and Trademark Office (USPTO) has issued Patent No. US 9,956,211 which protects BUPI, currently in development for pain due to oral mucositis. This patent should provide protection through to 2032.
2018-04-27
STOCKHOLM, April 27th 2018, Moberg Pharma AB (OMX: MOB) has completed the divestment of the Balmex® brand to Randob Labs for a total consideration of $4.25 million plus the inventory value. The divestment results in a capital gain of circa $0.5 million.
2018-04-26
STOCKHOLM, April 26st, 2018 - On May 8th 2018, at 08:00 am (CET), Moberg Pharma AB (OMX: MOB) will present its interim report for January - March 2018. Investors, analysts and journalists are hereby invited to participate in a teleconference at 3:00 pm (CET) on the same date.
2018-04-19
STOCKHOLM, April 19th, 2018, Moberg Pharma AB (OMX: MOB) announces that Kjell Rensfeldt, VP Research and Development, will retire in the fall but remain with the company part-time as Senior Adviser.
2018-04-10
Shareholders in Moberg Pharma AB (publ) (reg. no. 556697-7426) (the “Company”) are hereby convened to the Annual General Meeting on Tuesday, May 15, 2018 at 5:00 p.m. (CET) in the Company’s premises in Bromma, address Gustavslundsvägen 42, 5 tr, 167 51 Bromma (Alviks torg), Sweden.
2018-04-10
Moberg Pharma´s Annual Report for 2017 has been published and is available on www.mobergpharma.com
2018-03-13
STOCKHOLM, March 13th, 2018. Moberg Pharma AB (OMX: MOB) announces that the company’s Nomination Committee has decided to present the following proposal to the Annual General Meeting 2018.
2018-02-28
STOCKHOLM, February 28th 2018, Moberg Pharma AB (OMX: MOB) has entered into an agreement with Randob Labs to divest the brand Balmex® for a total consideration of $4.25 million (34.6 million SEK) plus the inventory value at closing. The divestment is expected to result in a capital gain of circa $0.5 million (4.4 million SEK), enabling Moberg Pharma to further focus resources on its larger brands.
2018-02-13
STRONG GROWTH FOR KERASAL NAIL INCREASES EBITDA
2018-02-06
STOCKHOLM, February 6th, 2018 - On February 13th 2018, at 08:00 am (CET), Moberg Pharma AB (OMX: MOB) will present its Year-end report 2017. Investors, analysts and journalists are hereby invited to participate in a teleconference at 03:00 pm (CET) on the same date.
2018-01-15
STOCKHOLM, January 15th, 2018 - Moberg Pharma AB (OMX: MOB) have received a positive outcome from the NAD (National Advertising Division) regarding a challenge filed on Fungi-Nail, the largest U.S. competitor to the Kerasal Nail® product. NAD recommends the advertiser to discontinue current product packaging and commercials. Moberg Pharma expects the outcome to further strengthen Kerasal Nails® position and growth prospects in the U.S. market.